Claims for Patent: 5,439,824
✉ Email this page to a colleague
Summary for Patent: 5,439,824
Title: | Increased expression of .alpha.-1-antitrypsin in expression vectors through the inclusion of intron II |
Abstract: | The present invention relates to novel expression vectors and a method to increase the expression of .alpha..sub.1 -antitrypsin (AAT) from expression vectors encoding for the same through the inclusion of the Intron II sequence. Preferably, the Intron II sequence is included in its naturally occurring position, immediately after Exon II. Also, the invention is methods of therapy using the method and the expression vectors. |
Inventor(s): | Brantly; Mark (Silver Spring, MD), Laubach; Victor (Bethesda, MD) |
Assignee: | The United States of America (Washington, DC) |
Application Number: | 08/060,925 |
Patent Claims: | 1. An isolated DNA molecule encoding human .alpha..sub.1 -antitrypsin, said molecule comprising a set of introns and a set of exons, wherein said set of exons consists of Exons
II, III, IV and V of the human .alpha..sub.1 -antitrypsin gene, and said set of introns consists of Intron II and zero to two additional introns of the human .alpha..sub.1 -antitrypsin gene.
2. The isolated DNA of claim 1 wherein said Intron II is located between Exons II and III. 3. The isolated DNA molecule of claim 1 wherein said DNA molecule also includes Intron III of the human .alpha..sub.1 -antitrypsin gene. 4. The isolated DNA molecule of claim 1 wherein said DNA molecule also includes Intron IV of the human .alpha..sub.1 -antitrypsin gene. 5. The isolated DNA of claim 1 wherein said DNA is in a vector. 6. The isolated DNA of claim 5 wherein said vector is an expression vector. 7. The isolated DNA of claim 6 wherein said vector is pPI. 8. The isolated DNA of claim 6 wherein said vector is a viral vector. |
Details for Patent 5,439,824
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2039-02-26 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.